In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here: Race identified as risk factor for VTE after pulmonary resection for lung cancer FDA approves Rybrevant for treatment of non-small cell lung cancer Behavioral health disorders have a 'big impact' on cancer surgery outcomes Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer References: Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005. Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954. Press Release Press Release Press Release

Ver todos los episodios